Analytical Data
-
基因名
PPARG
- Application
-
别名
PPARG;NR1C3;Peroxisome proliferator-activated receptor gamma
-
种属
Human
-
表达系统
E. coli
-
标签
N-6His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P37231
-
表达区间
157~274aa
-
分子量
15kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Identification
Protein Description
PPARG, or Peroxisome Proliferator-Activated Receptor Gamma, is a nuclear receptor that plays a crucial role in regulating glucose and lipid metabolism, making it a significant target in the study of metabolic disorders such as obesity and type 2 diabetes. As a transcription factor, PPARG influences the expression of genes involved in fatty acid storage and glucose metabolism, thereby mediating effects on insulin sensitization and inflammation. Research into recombinant PPARG proteins has gained prominence due to their potential therapeutic applications in metabolic diseases, as well as their role in adipogenesis and cardiovascular health. Given that PPARG agonists, such as thiazolidinediones, have been used clinically, understanding the structural and functional properties of recombinant PPARG can lead to the development of more effective and targeted treatments. Additionally, studies of PPARG's interaction with various ligands can provide insights into the molecular mechanisms underlying its regulatory functions, further enhancing the capacity for rational drug design. Overall, the exploration of recombinant PPARG is essential for unraveling its complex biological roles and for advancing therapeutic strategies in managing metabolic diseases.
